Search

Your search keyword '"Vermorken, Jan B."' showing total 982 results
Start Over Author "Vermorken, Jan B."
982 results on '"Vermorken, Jan B."'

15. Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses

Author

LIMKIN, Elaine, primary, BLANCHARD, Pierre, additional, LACAS, Benjamin, additional, BOURHIS, Jean, additional, PARMAR, Mahesh, additional, LICITRA, Lisa, additional, LE, Quynh-Thu, additional, YOM, Sue, additional, FORTPIED, Catherine, additional, LANGENDIJK, Johannes, additional, VERMORKEN, Jan B, additional, BERNIER, Jacques, additional, OVERGAARD, Jens, additional, HARRIS, Jonathan, additional, PIGNON, Jean-Pierre, additional, and AUPERIN, Anne, additional

Published
2023
Full Text
View/download PDF

16. Treatment in the Elderly

Author

Szturz, Petr, Vermorken, Jan B., Vermorken, Jan B., editor, Budach, Volker, editor, Leemans, C. René, editor, Machiels, Jean-Pascal, editor, Nicolai, Piero, editor, and O'Sullivan, Brian, editor

Published
2017
Full Text
View/download PDF

17. Immunotherapeutic Approaches

Author

Szturz, Petr, Vermorken, Jan B., Vermorken, Jan B., editor, Budach, Volker, editor, Leemans, C. René, editor, Machiels, Jean-Pascal, editor, Nicolai, Piero, editor, and O'Sullivan, Brian, editor

Published
2017
Full Text
View/download PDF

21. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

Author

Burtness, Barbara, Bourhis, Jean P, Vermorken, Jan B, Harrington, Kevin J, and Cohen, Ezra EW

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Rare Diseases, Dental/Oral and Craniofacial Disease, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Afatinib, Antineoplastic Agents, Carcinoma, Squamous Cell, Chemoradiotherapy, Chemotherapy, Adjuvant, Clinical Protocols, Disease-Free Survival, Double-Blind Method, ErbB Receptors, Head and Neck Neoplasms, Humans, Molecular Targeted Therapy, Neoplasm Recurrence, Local, Neoplasm Staging, Protein Kinase Inhibitors, Quality of Life, Quinazolines, Research Design, Risk Factors, Squamous Cell Carcinoma of Head and Neck, Time Factors, Treatment Outcome, Adjuvant, Head and neck, Local advanced, Phase III, Unfavourable risk, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, General & Internal Medicine, Clinical sciences, Epidemiology, Health services and systems
Abstract

BackgroundOver 50% of patients with head and neck squamous cell carcinoma (HNSCC) present with locoregionally advanced disease. Those at intermediate-to-high risk of recurrence after definitive therapy exhibit advanced disease based on tumour size or lymph node involvement, non-oropharynx primary sites, human papillomavirus (HPV)-negative oropharyngeal cancer, or HPV-positive oropharynx cancer with smoking history (>10-pack-years). Non-surgical approaches include concurrent chemoradiotherapy, induction chemotherapy followed by definitive radiotherapy or chemoradiotherapy, or radiotherapy alone. Following locoregional therapies (including surgical salvage of residual cervical nodes), no standard intervention exists. Overexpression of epidermal growth factor receptor (EGFR), an ErbB family member, is associated with poor prognosis in HNSCC. EGFR-targeted cetuximab is the only targeted therapy that impacts overall survival and is approved for HNSCC in the USA or Europe. However, resistance often occurs, and new approaches, such as targeting multiple ErbB family members, may be required. Afatinib, an irreversible ErbB family blocker, demonstrated antiproliferative activity in preclinical models and comparable clinical efficacy with cetuximab in a randomized phase II trial in recurrent or metastatic HNSCC. LUX-Head & Neck 2, a phase III study, will assess adjuvant afatinib versus placebo following chemoradiotherapy in primary unresected locoregionally advanced intermediate-to-high-risk HNSCC.Methods/designPatients with primary unresected locoregionally advanced HNSCC, in good clinical condition with unfavourable risk of recurrence, and no evidence of disease after chemoradiotherapy will be randomized 2:1 to oral once-daily afatinib (40 mg starting dose) or placebo. As HPV status will not be determined for eligibility, unfavourable risk is defined as non-oropharynx primary site or oropharynx cancer in patients with a smoking history (>10 pack-years). Treatment will continue for 18 months or until recurrence or unacceptable adverse events occur. The primary endpoint measure is duration of disease-free survival; secondary endpoint measures are disease-free survival rate at 2 years, overall survival, health-related quality of life and safety.DiscussionGiven the unmet need in the adjuvant treatment of intermediate-to-high-risk HNSCC patients, it is expected that LUX-Head & Neck 2 will provide new insights into treatment in this setting and might demonstrate the ability of afatinib to significantly improve disease-free survival, compared with placebo.Trial registrationClinicalTrials.gov NCT01345669.

Published
2014

22. Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature

Author

Bossi, Paolo, Alfieri, Salvatore, Strojan, Primoz, Takes, Robert P., López, Fernando, Mäkitie, Antti, Saba, Nabil F., Rodrigo, Juan Pablo, Bradford, Carol, Suarez, Carlos, Zafereo, Mark, Forastiere, Arlene A., Vermorken, Jan B., Quer, Miquel, Sanabria, Alvaro, Simo, Ricard, de Bree, Remco, Rinaldo, Alessandra, and Ferlito, Alfio

Published
2019
Full Text
View/download PDF

28. Critical Issues in Head and Neck Oncology

Author

Vermorken, Jan B., Budach, Volker, Leemans, C. René, Machiels, Jean-Pascal, Nicolai, Piero, and O'Sullivan, Brian

Subjects
Head and Neck Cancer, Predictive markers, Non-orophayngeal head and neck cancer, Induction chemotherapy, Radiation Oncology, Surgical Oncology, Liquid biopsies, Precision medicine, HNSCC, Nasopharynx cancer, Immunotherapy, Personalized Medicine, thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology, thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKS Medical imaging::MKSH Medical imaging: radiology
Abstract

This is an open access book. With a wealth of exciting data emerging in this rapidly evolving field this book will review the state-of-the-art knowledge with emphasis on multidisciplinary decision and management of head and neck cancer. The book provides significant detail on a wide range of topics including: the role of new targets for treatment, immunotherapy, resistance mechanisms, standardizing molecular profiling programs, and new methods to guide therapeutic approaches. In addition different disease situations are addressed including different treatment approaches in primary disease and in recurrent and/or metastatic disease as well as new developments in pathology, surgery and reconstruction techniques, new systemic therapies in salivary gland cancer, and supportive care and follow-up. All disciplines involved in the treatment of head & neck cancer are covered with a focus on translation into daily practice. The 8th-THNO is designed for medical oncologists, head and neck surgeons, radiation oncologists, otolaryngologists, and other medical professionals involved in the treatment of patients with head and neck cancer.

Published
2023
Full Text
View/download PDF

30. Supplementary Table 2 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer

Author

de Weger, Vincent A., primary, Turksma, Annelies W., primary, Voorham, Quirinus J.M., primary, Euler, Zelda, primary, Bril, Herman, primary, van den Eertwegh, Alfons J., primary, Bloemena, Elisabeth, primary, Pinedo, Herbert M., primary, Vermorken, Jan B., primary, van Tinteren, Harm, primary, Meijer, Gerrit A., primary, and Hooijberg, Erik, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 2 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer

Author

de Weger, Vincent A., primary, Turksma, Annelies W., primary, Voorham, Quirinus J.M., primary, Euler, Zelda, primary, Bril, Herman, primary, van den Eertwegh, Alfons J., primary, Bloemena, Elisabeth, primary, Pinedo, Herbert M., primary, Vermorken, Jan B., primary, van Tinteren, Harm, primary, Meijer, Gerrit A., primary, and Hooijberg, Erik, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 1 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer

Author

de Weger, Vincent A., primary, Turksma, Annelies W., primary, Voorham, Quirinus J.M., primary, Euler, Zelda, primary, Bril, Herman, primary, van den Eertwegh, Alfons J., primary, Bloemena, Elisabeth, primary, Pinedo, Herbert M., primary, Vermorken, Jan B., primary, van Tinteren, Harm, primary, Meijer, Gerrit A., primary, and Hooijberg, Erik, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 1 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer

Author

de Weger, Vincent A., primary, Turksma, Annelies W., primary, Voorham, Quirinus J.M., primary, Euler, Zelda, primary, Bril, Herman, primary, van den Eertwegh, Alfons J., primary, Bloemena, Elisabeth, primary, Pinedo, Herbert M., primary, Vermorken, Jan B., primary, van Tinteren, Harm, primary, Meijer, Gerrit A., primary, and Hooijberg, Erik, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 3 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer

Author

de Weger, Vincent A., primary, Turksma, Annelies W., primary, Voorham, Quirinus J.M., primary, Euler, Zelda, primary, Bril, Herman, primary, van den Eertwegh, Alfons J., primary, Bloemena, Elisabeth, primary, Pinedo, Herbert M., primary, Vermorken, Jan B., primary, van Tinteren, Harm, primary, Meijer, Gerrit A., primary, and Hooijberg, Erik, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure 4 from Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer

Author

de Weger, Vincent A., primary, Turksma, Annelies W., primary, Voorham, Quirinus J.M., primary, Euler, Zelda, primary, Bril, Herman, primary, van den Eertwegh, Alfons J., primary, Bloemena, Elisabeth, primary, Pinedo, Herbert M., primary, Vermorken, Jan B., primary, van Tinteren, Harm, primary, Meijer, Gerrit A., primary, and Hooijberg, Erik, primary

Published
2023
Full Text
View/download PDF

37. Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer

Author

Saba, Nabil F., primary, Pamulapati, Saagar, additional, Patel, Bhamini, additional, Mody, Mayur, additional, Strojan, Primož, additional, Takes, Robert, additional, Mäkitie, Antti A., additional, Cohen, Oded, additional, Pace-Asciak, Pia, additional, Vermorken, Jan B., additional, Bradford, Carol, additional, Forastiere, Arlene, additional, Teng, Yong, additional, Wieland, Andreas, additional, and Ferlito, Alfio, additional

Published
2023
Full Text
View/download PDF

45. Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus

Author

Mirabile, Aurora, Numico, Gianmauro, Russi, Elvio G., Bossi, Paolo, Crippa, Fulvio, Bacigalupo, Almalina, De Sanctis, Vitaliana, Musso, Stefania, Merlotti, Anna, Ghi, Maria Grazia, Merlano, Marco C., Licitra, Lisa, Moretto, Francesco, Denaro, Nerina, Caspiani, Orietta, Buglione, Michela, Pergolizzi, Stefano, Cascio, Antonio, Bernier, Jacques, Raber-Durlacher, Judith, Vermorken, Jan B., Murphy, Barbara, Ranieri, Marco V., and Dellinger, R. Phillip

Published
2015
Full Text
View/download PDF

46. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Author

Machiels, Jean-Pascal H, Haddad, Robert I, Fayette, Jérôme, Licitra, Lisa F, Tahara, Makoto, Vermorken, Jan B, Clement, Paul M, Gauler, Thomas, Cupissol, Didier, Grau, Juan José, Guigay, Joël, Caponigro, Francesco, de Castro, Gilberto, Jr, de Souza Viana, Luciano, Keilholz, Ulrich, del Campo, Joseph M, Cong, Xiuyu Julie, Ehrnrooth, Eva, and Cohen, Ezra E W

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results